Top

BMC Infectious Diseases

Published in:

Open Access 01-12-2021 | Hepatitis B | Research article

Changing trends in seroprevalence rates of transfusion-transmitted diseases among blood donors in Jordan

Authors: Lina Souan, Mahmoud Siag, Hala Al-Salahat, Tareq Al-Atrash, Maher A. Sughayer

Published in: BMC Infectious Diseases | Issue 1/2021

Abstract

Background

Hepatitis B and C infections and transmission are a serious challenge to all healthcare systems. We studied seroprevalence rates of Transfusion Transmitted Diseases (TTD) among blood bank donors in Jordan from 2014 to 2019 as a follow-up study of our previously published work. In addition, we wanted to explore the efficacy of the mandatory vaccination of infants against hepatitis B virus (HBV) which was implemented by the Ministry of Health since 1995 for the eradication of HBV infection in Jordan.

Methods

We reviewed blood bank donors’ records at King Hussein Cancer Center (KHCC) from January 1st, 2014, until December 31st, 2019. Results of seropositivity prevalence rates for HBsAg, anti-HBcore, and anti-HCV, using Enzyme-Linked ImmunoSorbent Assay (ELISA) were compared to seropositivity rates from our previously published data. In addition, our results were compared to data obtained from other blood banks in Jordan, as well as compared to published information from blood banks in neighboring countries.

Results

The prevalence rates (%) of seropositive blood donors for viral hepatitis for the years 2014, 2015, 2016, 2017, 2018, and 2019, were as follows: HBsAg rates were 0.3386, 0.2108, 0.1801, 0.1898, 0.2068, and 0.2741; anti-HBcore rates were 4.1112, 3.2271, 2.9748, 2.8405, 2.6879 and 3.0986; and anti-HCV rates were 0.1129, 0.0486, 0.0548, 0.0654, 0.0782, and 0.0839, respectively. There was a significant increase in the prevalence of HBsAg, Anti-HBcore and Anti-HCV antibodies in 2019 (one sample z-score test, p < 0.00001).

Conclusions

Prevalence rates of hepatitis B and C infections among Jordanian blood bank donors showed a steady decline between 2009 and 2017, and these rates were much lower in Jordan than in neighboring countries. However, an increase in the prevalence rates of hepatitis B and C infections among blood bank donors was documented in 2019. While the reasons for this increase are not clear yet, these findings highlight the importance of renewed efforts to increase public health awareness of HBV and implement effective measures to prevent the transmission and infection with HBV, including national vaccination programs.

Babanejad M, Izadi N, Najafi F, Alavian SM. The HBsAg prevalence among blood donors from eastern Mediterranean and middle eastern countries: a systematic review and meta-analysis. Hepat Mon. 2016;16(3):e35664. https://doi.org/10.5812/hepatmon.35664.CrossRefPubMedPubMedCentral

Souan L, Tout F, Siag M, Sughayer MA. Seroprevalence rates of transfusion-transmitted infections among blood donors in Jordan. J Infect Dev Ctries. 2016;10(4):377–83. https://doi.org/10.3855/jidc.8160.CrossRefPubMed

Chandra T, Rizvi SN, Agarwal D. Decreasing prevalence of transfusion transmitted infection in Indian scenario. ScientificWorldJournal. 2014;2014:173939.CrossRef

Transfusion Medicine Checklist [https://elss.cap.org/elss/faces/org/cap/elss/ui/page/elssmain.jspx?_afrLoop=765207228138376&_afrWindowMode=0&_afrWindowId=null#!%40%40%3F_afrWindowId%3Dnull%26_afrLoop%3D765207228138376%26_afrWindowMode%3D0%26_adf.ctrl-state%3D107ozyq29i_4].

Murex HBsAg, Version 3 ELISA Infectious disease [package insert]. DiaSorin: Saluggia (VC), Italy; 2005. https://www.diasorin.com/sites/default/files/allegati_prodotti/Murex%20HBsAG%20Version%203.pdf.

Monolisa™ HBs Ag ULTRA [package insert]. Marnes-la-Coquette: Bio-Rad; 2011. https://www.biorad.com/webroot/web/pdf/inserts/CDG/en/883614_EN.pdf.

HBsAg Qualitative [package insert]. Abbott Park: Abbott; 2011.

HBsAg II [package insert]. Indianapolis: Roche Diagnostics; 2017.

Monolisa™ Anti-HBc PLUS [package insert]. Marnes-la-Coquette: Bio-Rad; 2009. https://www.bioRad.com/webroot/web/pdf/inserts/CDG/en/Literature/inserts/883565_GB.pdf.

10.

Anti-HBc II [package insert]. Abbott Park: Abbott; 2008.

11.

Anti-HBc, Antibodies to hepatitis B core antigen (anti-HBc) [package insert]. Indianapolis: Roche Diagnostics; 2017.

12.

Anti-HCV Elisa 4.0 [package insert]. Louvain-la-Neuve: DIAsource ImmunoAssays SA; 2019.

13.

Anti-HCV [package insert] Abbott: Abbott Park; 2006.

14.

Anti-HCV II, Antibody to hepatitis C virus (anti-HCV) [package insert]. Indianapolis: Roche Diagnostics; 2017.

15.

N RH. Risk factors of hepatitis B virus infection among blood donors in Duhok city, Kurdistan region, Iraq. Caspian J Intern Med. 2018;9(1):22–6. https://doi.org/10.22088/cjim.9.1.22.CrossRef

16.

Aljumah AA, Babatin M, Hashim A, Abaalkhail F, Bassil N, Safwat M, et al. Hepatitis B care pathway in Saudi Arabia: current situation, gaps and actions. Saudi J Gastroenterol. 2019;25(2):73–80. https://doi.org/10.4103/sjg.SJG_421_18.CrossRefPubMedPubMedCentral

17.

Saab BR, Nassar NT, Musharrafieh U, Araj GF, Khogali M. Prevalence of hepatitis B in a presumably healthy Lebanese population. J Med Liban. 2007;55(1):11–4.PubMed

18.

Hussein E. Blood donor recruitment strategies and their impact on blood safety in Egypt. Transfus Apher Sci. 2014;50(1):63–7. https://doi.org/10.1016/j.transci.2013.11.005.CrossRefPubMed

19.

Alaidarous M, Choudhary RK, Waly MI, Mir S, Bin Dukhyil A, Banawas SS, et al. The prevalence of transfusion-transmitted infections and nucleic acid testing among blood donors in Majmaah, Saudi Arabia. J Infect Public Health. 2018;11(5):702–6. https://doi.org/10.1016/j.jiph.2018.04.008.CrossRefPubMed

20.

Yalcin Bahat P, Turan G, Yuksel Ozgor B, Bagci Cakmak K. Comparison of hepatitis B, hepatitis C, and HIV seropositivity of Syrian and Turkish pregnant women. Turk J Obstet Gynecol. 2019;16(2):95–9. https://doi.org/10.4274/tjod.galenos.2019.15564.CrossRefPubMedPubMedCentral

21.

Vittal A, Ghany MG. WHO guidelines for prevention, care and treatment of individuals infected with HBV: a US perspective. Clin Liver Dis. 2019;23(3):417–32. https://doi.org/10.1016/j.cld.2019.04.008.CrossRefPubMed

22.

Al Romaihi HE, Ganesan N, Farag EA, Smatti MK, Nasrallah GK, Himatt SM, Derbala MF, Alshamali M, Mahadoon LK, Khogali HS, Sallam M, Al Thani AA, Al Thani M, Al Kaabi S, Yassine HM. Demographics and Epidemiology of Hepatitis B in the State of Qatar: A Five-Year Surveillance-Based Incidence Study. Pathogens. 2019;8(2):68. https://doi.org/10.3390/pathogens8020068.

23.

Daly MC, Duncan GJ, McDonough P, Williams DR. Optimal indicators of socioeconomic status for health research. Am J Public Health. 2002;92(7):1151–7. https://doi.org/10.2105/ajph.92.7.1151.CrossRefPubMedPubMedCentral

24.

Al Humayed SM, El-Mekki AA, Mahfouz AA. Hepatitis C virus infection in southwestern Saudi Arabia: are we still in the plateau phase? J Med Virol. 2017;89(5):867–71. https://doi.org/10.1002/jmv.24712.CrossRefPubMed

25.

Hashish MH, El-Barrawy MA, Mahmoud OA, Abdel Rahman NW. TT virus among blood donors in Alexandria. J Egypt Public Health Assoc. 2005;80(5–6):651–64.PubMed

26.

Irfan SM, Uddin J, Zaheer HA, Sultan S, Baig A. Trends in transfusion transmitted infections among replacement blood donors in Karachi, Pakistan. Turk J Haematol. 2013;30(2):163–7. https://doi.org/10.4274/Tjh.2012.0132.CrossRefPubMedPubMedCentral

27.

Jary A, Dienta S, Leducq V, Le Hingrat Q, Cisse M, Diarra AB, et al. Seroprevalence and risk factors for HIV, HCV, HBV and syphilis among blood donors in Mali. BMC Infect Dis. 2019;19(1):1064. https://doi.org/10.1186/s12879-019-4699-3.CrossRefPubMedPubMedCentral

28.

Okoroiwu HU, Okafor IM, Asemota EA, Okpokam DC. Seroprevalence of transfusion-transmissible infections (HBV, HCV, syphilis and HIV) among prospective blood donors in a tertiary health care facility in Calabar, Nigeria; an eleven years evaluation. BMC Public Health. 2018;18(1):645. https://doi.org/10.1186/s12889-018-5555-x.CrossRefPubMedPubMedCentral

29.

Pessoni LL, Aquino EC, Alcantara KC. Prevalence and trends in transfusion-transmissible infections among blood donors in Brazil from 2010 to 2016. Hematol Transfus Cell Ther. 2019;41(4):310–5. https://doi.org/10.1016/j.htct.2019.03.009.CrossRefPubMedPubMedCentral

30.

Arefkhah N, Vafazadeh S, Shahriarirad S, Ghorbani F, Zoghi S, Emami M, et al. Serum levels of anti-hepatitis B surface antibodies among vaccinated children aged 1 to 12 years in a rural community in Fars Province, southern Iran. J Immunoassay Immunochem. 2020;41(1):20–7. https://doi.org/10.1080/15321819.2019.1675696.CrossRefPubMed

31.

Di Lello FA, Blejer J, Alter A, Bartoli S, Vargas F, Ruiz R, et al. Hepatitis B surface antibodies seroprevalence among people born before and after implementation of universal HBV vaccination. Vaccine. 2020;38(12):2678–82. https://doi.org/10.1016/j.vaccine.2020.02.014.CrossRefPubMed

32.

Hefele L, Vannachone S, Khounvisith V, Nouanthong P, Sayasone S, Kounnavong S, et al. Lasting benefit of infant hepatitis B vaccination in adolescents in the Lao People's Democratic Republic. Int J Infect Dis. 2020;93:217–23. https://doi.org/10.1016/j.ijid.2020.01.055.CrossRefPubMed

33.

Yang YT, Huang AL, Zhao Y. The prevalence of hepatitis B core antibody in vaccinated Chinese children: a hospital-based study. Vaccine. 2019;37(3):458–63. https://doi.org/10.1016/j.vaccine.2018.11.067.CrossRefPubMed

34.

Gore C, Wiktor S, Goldberg D, Hutchinson S, Onate Moreno JA, Peck R. Roundtable discussion: how the world hepatitis summit 2015 strengthened stakeholders' efforts to combat viral hepatitis. Hepatol Med Policy. 2016;1(1):12. https://doi.org/10.1186/s41124-016-0018-4.CrossRefPubMedPubMedCentral

Title: Changing trends in seroprevalence rates of transfusion-transmitted diseases among blood donors in Jordan
Authors: Lina Souan
Mahmoud Siag
Hala Al-Salahat
Tareq Al-Atrash
Maher A. Sughayer
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Hepatitis B
Published in: BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-021-06196-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Changing trends in seroprevalence rates of transfusion-transmitted diseases among blood donors in Jordan

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

An easy-to-use nomogram for predicting in-hospital mortality risk in COVID-19: a retrospective cohort study in a university hospital

Infection pattern, case fatality rate and spread of Lassa virus in Nigeria

Effect of mobile-phone messaging on patient and health-worker knowledge and adherence to the isoniazid preventive therapy guideline in HIV clinics in Southeast, Nigeria

Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study

Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia

Assessing the impact of HIV support groups on antiretroviral therapy adherence and viral suppression in the African cohort study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page